AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,743.00GBp
30 Jan 2015
Change (% chg)

-18.50p (-0.39%)
Prev Close
4,761.50p
Open
4,756.00p
Day's High
4,797.00p
Day's Low
4,684.50p
Volume
3,746,512
Avg. Vol
2,382,957
52-wk High
4,946.41p
52-wk Low
3,663.70p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.40
Market Cap(Mil.): £59,910.89
Shares Outstanding(Mil.): 1,263.14
Dividend: 53.10
Yield (%): 3.58

Financials

  AZN.L Industry Sector
P/E (TTM): 87.94 37.76 38.54
EPS (TTM): 0.54 -- --
ROI: 2.60 18.79 18.06
ROE: 4.71 19.44 18.83
Search Stocks

AstraZeneca bets on 'genetic scissors' for range of new drugs

LONDON - AstraZeneca said on Thursday it had struck four research agreements in the hot area of genome editing as it bets on a new "genetic scissors" technology to deliver better and more precise drugs for a range of diseases.

29 Jan 2015

UPDATE 2-AstraZeneca bets on "genetic scissors" for range of new drugs

* Builds on in-house CRISPR programme at drugmaker (Adds further details on promise of new technology)

29 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

28 Jan 2015

UPDATE 1-FDA approves Teva's generic version of AstraZeneca's Nexium

Jan 26 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

26 Jan 2015

AstraZeneca heart drug boosted by major clinical trial success

LONDON - AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

14 Jan 2015

UPDATE 2-AstraZeneca heart drug boosted by major clinical trial success

* AstraZeneca shares up 1.5 percent (Adds executive interview, consensus sales forecast, more reaction)

14 Jan 2015

Europe shares fall as growth fears hit energy, miners

LONDON, Jan 14 - European shares fell at the open on Wednesday, mirroring a slump in copper and oil prices after the World Bank cut its global growth forecast for this year.

14 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

- Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

KARLSRUHE, Germany - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

AstraZeneca loses German court appeal over Seroquel XR drug patent

KARLSRUHE, Germany, Jan 13 - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

13 Jan 2015

Earnings vs. Estimates

Search Stocks